Stephenson Global Scholar Grants Program Awards $5.3 Million to Drive Breakthroughs in Pancreatic Cancer Research
The grants support a new generation of research that is collaborative, cross-institutional, and deeply innovative. The 2025 recipients are tackling some of the most urgent and complex challenges in pancreatic cancer—from using AI to flag high-risk patients for screening, to developing dual-targeting CAR T cells that attack both tumors and their fibrotic defenses, to uncovering how diabetes-linked DNA damage may trigger cancer. Their work spans early detection, immunotherapy, metabolic vulnerabilities, and precision medicine—and reflects the kind of interdisciplinary, translational science that is urgently needed to improve outcomes for patients.
2025 Stephenson Scholar Grant Recipients
Dr. Renier Brentjens and Dr. Leonid Cherkassky (Roswell Park)
Engineering Circuit-controlled T Cell Differentiation and Restructuring the Pancreatic Cancer Stroma to Optimize PDAC-targeted CAR T Cell Therapy for Clinical Translation
Creating next-generation CAR T cells that target both pancreatic tumors and their fibrotic stroma, using synthetic promoters to fine-tune T cell behavior, offering a promising new direction for pancreatic cancer immunotherapy.
Dr. Robert Grant (Princess Margaret/UHN)
Applying Artificial Intelligence to Electronic Health Records to Guide Pancreatic Cancer Screening
Utilizing large language models to analyze EHR data and flag high-risk individuals for screening—embedding AI directly into hospital systems to enable scalable early detection.
Dr. Costas Lyssiotis (University of Michigan)
Lysosomal Lipid Homeostasis is a Clinically Exploitable Vulnerability in KRAS-Inhibited Pancreatic Cancer
Targeting a unique metabolic vulnerability in KRAS-mutant tumors using clinically relevant drugs and synthetic lethality, with durable cures shown in preclinical models.
Dr. Sarah Shuck (City of Hope)
From Blood Sugar to Tumor Growth: How Diabetes Fuels Pancreatic Cancer Onset
Investigating how the sugar byproduct methylglyoxal leads to DNA mutations associated with pancreatic cancer and developing a novel blood-based screening tool.
Dr. Matthew Vander Heiden (MIT)
Assessment of Pancreas Organ Health for Pancreatic Cancer Early Detection
Developing a multimodal platform that combines stool, blood, and CT imaging to detect pancreatic cancer before symptoms appear and leveraging changes in organ function as early warning signs.
Dr. Forest White & Dr. Tyler Jacks (MIT)
Identification of Treatment-Associated Tumor Antigens for Targeted Immunotherapy in Pancreatic Cancer
Using mass spectrometry to identify new peptide antigens that emerge after KRAS inhibition, enabling novel vaccine and BiTE strategies that link targeted therapy with immunotherapy.
'These scientists' pioneering approaches represent the future of pancreatic cancer research,' said A. Emmet Stephenson Jr., co-founder of SGPCRI. 'Their work exemplifies the kind of innovative, collaborative thinking that the Stephenson initiative was created to support.'
'Pancreatic cancer took my mother far too soon, but my father and I know that groundbreaking science can change the future for so many other families who have faced this disease,' said Tessa Stephenson Brand. 'These grants are about hope, urgency, and the belief that progress is possible.'
The Stephensons made their investment in honor of Toni Stephenson, loving wife and mother who, after surviving lymphoma, passed away from pancreatic cancer in 2020.
'Pancreatic cancer remains one of the most challenging diseases to detect and treat, but we are making meaningful progress,' said Dr. Matthew Vander Heiden, the Lester Wolfe Chair in Molecular Biology and Professor of Biology at MIT. 'We're particularly encouraged by the potential to identify changes in normal pancreas function that could enable earlier detection—when treatment is most effective. The opportunity to rigorously test this idea is incredibly exciting, and I'm deeply grateful to the Stephenson Global Pancreatic Cancer Research Institute for supporting this ambitious work. Their investment in innovative research is helping move discoveries closer to the patients who need them most.'
A Collaborative Vision for a Global Challenge
The Stephenson Scholar Grants represent the largest source of private funding for pancreatic cancer research around the globe. Pancreatic cancer remains the deadliest cancer with a five-year survival rate of just 13% in the United States, impacting hundreds of thousands of families each year. The grants come at a time when federal funding for cancer research—already disproportionately low for pancreatic cancer—is facing an uncertain future.
These grants reflect the Institute's commitment to building a global, collaborative research ecosystem. This year's recipients span leading institutions in the U.S. and Canada, and their projects are designed to bridge disciplines, labs, and clinical settings. The winners were selected from a competitive pool of 188 applications spanning six continents, following a rigorous review by the Stephenson Scientific Advisory Board, comprising some of the world's foremost experts in pancreatic cancer.
The grants are part of a broader vision launched with a transformative $150 million gift from A. Emmet Stephenson Jr. and Tessa Stephenson Brand to accelerate discovery, foster partnership, and bring hope to patients and families worldwide. They selected City of Hope, a National Cancer Institute-designated comprehensive cancer center with a national footprint, to help facilitate the SGPCRI's various initiatives and bring together pancreatic cancer leaders in the search for new breakthroughs.
'Congratulations to the inaugural recipients of the Stephenson Global Scholar Grants,' said Daniel D. Von Hoff, M.D., chair of the Stephenson Scientific Advisory Board and distinguished professor at the Translational Genomics Research Institute, part of City of Hope. 'These awards support transformative approaches—from assessing pancreatic health and enabling earlier detection to advancing the latest immunotherapies. There has never been a more important time to unite around high-impact science. This teamwork between visionary philanthropists and some of the world's leading cancer institutions is bringing us closer to a future where pancreatic cancer is no longer a death sentence. We are also deeply grateful to the members of the Scientific Advisory Board for their wisdom and thoughtful deliberation in guiding this effort.'
For more information about the Stephenson Global Pancreatic Cancer Research Institute and the Stephenson Global Scholar Grants, visit sgpcri.global.
About the Stephenson Global Pancreatic Cancer Research Institute
The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is dedicated to transforming the future of pancreatic cancer research through groundbreaking innovation, global collaboration and strategic funding initiatives. Established through a transformative $150 million gift from philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand, SGPCRI is committed to advancing early detection, pioneering treatments and high-impact research to improve patient outcomes. Working with leading scientists, clinicians and institutions worldwide, SGPCRI fosters collaboration to accelerate breakthroughs in the fight against one of the world's most challenging cancers. For more information, visit us on our website or follow us on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
5 hours ago
- CNET
7 Simple Ways to Add Movement to Your Day (Without Dreading It)
I'm far from the first person to say it, but exercise is essential for your overall health. Exercise helps to boost your mood, relieve stress, increase energy, improve sleep quality and lower your risk for developing chronic illnesses and diseases, including diabetes, cardiovascular disease and high blood pressure. So, you might be wondering, if exercise is so important to our overall health, why can it be so miserable? Trust me, I get it. I live an active lifestyle, making an effort to work out four to five times per week, and yet I still have that mental debate every single day where I spend several minutes attempting to talk myself out of exercising. Although I never regret working out after the fact, it can be hard to jump the mental hoop. Over the years, I've found some easy tricks to get myself more active each day. No, going to the gym and doing a hard-core weight workout isn't required. There are actually sneaky ways to get more exercise day-to-day that won't leave you exhausted and miserable. Here's my secret sauce. For more health tips, learn about how to prepare for your first therapy appointment and how to determine your blood type if you don't already know it. 1. Set a routine CNET OK, so this isn't really a secret. Creating a regular habit of working out would be ideal -- duh! But it's creating that habit that's the tricky part. Here's where I can help. One of the most efficient ways to build a habit is through the Cue-Routine-Reward system. MIT researchers discovered the power of the neurological loop at the core of every habit. This "habit loop," later coined by Charles Duhigg in his 2012 book The Power of Habit, consists of three parts: a cue, a routine and a reward. This system can be applied to building any habit, from drinking more water to waking up earlier. It can certainly apply to creating a workout habit. For example, say you want to wake up and go to the gym each morning before work. The cue, what triggers the habit, would be the morning and your alarm going off. (Choose a time that works best for you and be consistent. Using multiple cues like time of day and sound can increase your likelihood of performing your routine.) Your routine, the habit or action you want to create and reinforce, would be getting up and changing into your workout clothes. This can help prevent you from going back to sleep and ensure you hit the gym since you're already ready. And once you finish the routine (the exercise), you'll be rewarded. This could appear in the form of endorphins as a bodily reward that can motivate us to do the routine again, or it could even be a tangible reward, like buying yourself new socks after a week of hitting your exercise goals or investing in a new yoga mat after a month of doing yoga each day. Each person will have a different response to these three elements. It's important to experiment with what cues and rewards work best for you to develop a consistent routine of training. 2. Start small A lot of people assume they need to run themselves ragged in the gym to get more fit, but that's really not true. All you need is about 20 or so minutes a day. The US Department of Health and Human Services recommends a minimum of 150 minutes of moderate aerobic activity a week -- that breaks down to a little more than 20 minutes each day. They also recommend strength training to work the major muscle groups at least two times a week. Thirty minutes of activity each day is an ideal place to start to fulfill your weekly needs, but if that sounds daunting, you can start with even smaller increments. Simply walking on the treadmill or cycling on a stationary bike for five minutes can get you into the habit of exercising a little each day. What you'll likely find is that those five minutes actually aren't too brutal, and are maybe even enjoyable. So, the next time you jump on the treadmill, bike or other equipment, you'll decide to stay for 10 minutes then 15 minutes then 20 minutes, building yourself up bit by bit until you're getting your heart rate up for 30-plus minutes each day. You can also start with low-impact activity. A brisk walk in the evening is a more than sufficient workout. You can also refer to this guide for the best workouts for beginners. 3. Habit stack Habit stacking, popularized by James Clear in his book Atomic Habits, is a way to create small yet healthy habits. This term might be new to you, but it's really straightforward: you "stack" the new behavior (exercising) onto a habit you already have to help you remember to do it. This will cause the combo to become a habit. For instance, if you listen to a podcast every day, try going for a walk while you listen. Waiting for your morning coffee to brew? Try stretching while you wait. Habit stacking can be used in a multitude of ways to make new fitness habits blend into your daily routine. Exercise while catching up on your favorite podcast. Ivanko_Brnjakovic/Getty Images 4. Get active at work Your workday doesn't have to be totally sedentary. Rather than using your full lunch hour to eat, take some time to go to the gym, speed walk around the office or run errands. You can also break up the drudgery of the day by taking a walk during one-on-one meetings instead of sitting at a desk or conference room -- anything to get up and get moving. Try to get up every so often to stretch your legs: rather than emailing or Zooming coworkers, get up and talk to them in person if you can; use the stairs rather than the elevator; get up and refill your water every so often. 5. Do exercises you actually like This is a big one. If you hate exercising, it might be because you aren't doing workouts you enjoy. Very few people actually enjoy running around in circles for miles. So don't. Branch out and try different kinds of workouts until you find one you genuinely enjoy. Biking, surfing, paddle boarding, yoga, hiking, skiing, rock climbing, kayaking and ice skating are all fun activities that get your heart rate up. This will require you to go out of your comfort zone and to be patient as you try things out, but it'll be worth it when working out no longer feels like a chore. One trick I used when first getting into working out was using the ClassPass free month trial to try new gyms and classes. The free first-month subscription allows you to visit a particular gym or studio only once throughout the month (you can visit as many times as you want throughout the month after the free trial). This plan is meant to encourage new users to try exercises that might be totally foreign to them, like reformer pilates or hot yoga. During my first month, I tried a boxing class and I was immediately hooked (pun only slightly intended). Now, boxing is one of my favorite ways to incorporate cardio without feeling miserable. I initially felt insecure about trying something so out of my comfort zone, but I felt comfortable within a week and now feel grateful that I found a new activity that I love. Exercise doesn't have to feel like a chore. gradyreese/Getty Images 6. Get active while watching TV Let's be honest, running on the treadmill is boring. Riding on a stationary bike is boring. Watching TV is way more fun. That's why you should combine the two. There's no shame in catching up on your favorite show while hitting the gym. Trust me, I've been rewatching Game of Thrones on my phone while riding on the stationary bike each day. Not only does the entertainment keep my mind off the burn in my legs, but it pushes me to stay longer. Before downloading Netflix and HBO Max on my phone, I'd stay at the gym for 20 to 30 minutes. Now, I usually stay on the bike or treadmill for 50 to 60 minutes -- until the episode is over. 7. Make it social Exercise doesn't need to be solitary. Having a workout partner can help keep you motivated and hold you accountable in your routine. If you don't have one buddy to join you, sign up for a workout class. The structure of working out in a group can push you to work harder while also introducing you to new people. Workout classes can hold you accountable -- and introduce you to new people. twinsterphoto/Getty Images I recommend exploring the fitness course schedule at your local YMCA or gym, signing up for a boxing, dance or yoga class or purchasing a ClassPass membership, which can grant you access to thousands of health clubs in your city. For more health tips, explore how you can track your blood pressure with your Apple Watch and learn why expired makeup is dangerous to use.
Epoch Times
a day ago
- Epoch Times
The Cognitive Debt We Accumulate Every Time We Use AI
When MIT researchers asked students to write essays with and without ChatGPT, the outcomes were concerning: 83 percent of those who used AI to draft their work couldn't recall a single sentence, even though they had written it just minutes before. The AI-induced amnesia exemplifies more than just a side effect of artificial intelligence. ChatGPT and similar AI-powered tools are now used daily and widely for everything from emails to essays. Yet, as the new study indicates, we may be sacrificing cognitive capacity and creativity for short-term convenience. AI-Induced Amnesia The MIT study included 54 participants from the Boston area. The students wrote essays under three conditions: using ChatGPT, using Google for research, or drawing entirely on their knowledge and reasoning. The researchers examined them in terms of memory, neural activation, and feelings of ownership.
Business Wire
2 days ago
- Business Wire
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.
